A Phase 3 interventional study of Ertugliflozin 5 mg and Ertugliflozin 15 mg in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed at 104 sites in 22 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-10-31.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.
Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 13th largest by enrollment, is one of 2 that started in 2019, is one of 11 in phase 3, and was the 22nd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Amsterdam UMC, location VUmc · Sites in United States, Netherlands
Ages 18–85
Baylor Research Institute · Sites in United States
Ages 18–84
Shanghai Zhongshan Hospital · Sites in China
Ages 19+
By country, each count listing its studies:
ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 166 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 83 across the 28 interventional studies. Of the 24 that completed or were terminated, 19 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 89th largest by enrollment of the 170 interventional ones that give a count, is the only one that started in 2019, is one of 86 in phase 3, and was the 179th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluated the safety and efficacy of ertugliflozin (MK-8835) in pediatric participants with T2DM on metformin with/without insulin. The primary hypothesis of the study was that the addition of ertugliflozin reduces hemoglobin A1C (HbA1C) more than the addition of placebo after 24 weeks of treatment.
Participants were randomized on Day 1 to the following arms:
At Week 12, participants who met the up-titration criteria were re-randomized to the following arms for Weeks 12 to 54:
The placebo arm continued receiving placebo from Week 12 to Week 54.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants initially received 5 mg ertugliflozin (ERTU) once daily (QD) and placebo to 15 mg ERTU QD until Week 54 (WK54). At Week 12 (WK12), participants who did not meet the up-titration criteria remained on 5 mg ERTU and placebo to 15 mg ERTU. Participants remained on their background metformin with/without insulin treatment throughout the study.
Drug: Ertugliflozin 5 mg · Drug: Placebo to ertugliflozin 15 mg · Biological: Insulin · Drug: Metformin
All participants initially received 5 mg ERTU QD and placebo to 15 mg ERTU QD until Week 12. Participants remained on their background metformin with/without insulin treatment throughout the study. Participants who met the up-titration criteria at the WK12 second randomization were re-randomized to remain on 5 mg ERTU and placebo to 15 mg ERTU from WK12 to WK54.
Drug: Ertugliflozin 5 mg · Drug: Placebo to ertugliflozin 15 mg · Biological: Insulin · Drug: Metformin
All participants initially received 5 mg ERTU QD and placebo to 15 mg ERTU QD until Week 12. Participants remained on their background metformin with/without insulin treatment throughout the study. Participants who met the up-titration criteria at the WK12 second randomization were up-titrated to 15 mg ERTU and placebo to 5 mg ERTU from WK12 to WK54.
Drug: Ertugliflozin 5 mg · Drug: Ertugliflozin 15 mg · Drug: Placebo to ertugliflozin 15 mg · Drug: Placebo to ertugliflozin 5 mg · Biological: Insulin · Drug: Metformin
All participants received matched placebo to 5 mg ERTU and 15 mg ERTU from baseline to WK54. Participants remained on their background metformin with/without insulin treatment throughout the study.
Drug: Placebo to ertugliflozin 15 mg · Drug: Placebo to ertugliflozin 5 mg · Biological: Insulin · Drug: Metformin
Ertugliflozin 5 mg, oral, 1 tablet QD
Also known as: MK-8835, PF-04971729
Ertugliflozin 15 mg, oral, 1 tablet QD
Also known as: MK-8835, PF-04971729
Placebo to ertugliflozin 15 mg, oral, 1 tablet QD
Placebo to ertugliflozin 5 mg, oral, 1 tablet QD
Participants on insulin at screening continued to receive a stable dose of background insulin. The initiation and titration of insulin for rescue therapy was at the discretion of the investigator, based on local/regional/country guidelines.
Participants received stable dose of background metformin.
Change From Baseline in Hemoglobin A1C (HbA1C) at Week 24 (Combined Ertugliflozin Versus Placebo)
Hemoglobin A1C is a measure of the percentage of glycated HbA1C in the blood. Participant whole blood samples were collected at baseline and Week 24 to determine the A1C change from baseline (i.e., % A1C at Week 24 minus % A1C at baseline). A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. The Bayesian mean change from baseline for each combined ertugliflozin and placebo are reported. Per protocol, the ertugliflozin arms are combined for this analysis.
Time frame: Baseline and Week 24
Number of Participants Who Experienced an Adverse Event (AE) Up to Week 24
An adverse event -- Select --is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. Per protocol, the ertugliflozin arms are combined for this analysis.
Time frame: Up to Week 24
Number of Participants Who Experienced an AE Up to Week 54
An adverse event is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. Per protocol, the ertugliflozin arms are combined for this analysis.
Time frame: Up to Week 54
Number of Participants Who Discontinued Study Treatment Due to an AE Up to Week 24
An adverse event is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. Per protocol, the ertugliflozin arms are combined for this analysis.
Time frame: Up to Week 24
Number of Participants Who Discontinued Study Treatment Due to an AE Up to Week 54
An adverse event is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. Per protocol, the ertugliflozin arms are combined for this analysis.
Time frame: Up to Week 54
Change From Baseline in Hemoglobin A1C at Week 24 (Dose-optimized Ertugliflozin Versus Placebo)
Hemoglobin A1C is a measure of the percentage of glycated HbA1C in the blood. Participant whole blood samples were collected at baseline and Week 24 to determine the A1C change from baseline (i.e., % A1C at Week 24 minus % A1C at baseline). A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Week 24
Change From Baseline in Hemoglobin A1C at Week 24 (5 mg Ertugliflozin Versus Placebo)
Hemoglobin A1C is a measure of the percentage of glycated HbA1C in the blood. Participant whole blood samples were collected at baseline and Week 24 to determine the A1C change from baseline (i.e., % A1C at Week 24 minus % A1C at baseline). A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Week 24
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
Blood glucose is measured on a fasting basis. FPG is expressed as mg/dL. Blood was drawn at predose on Day 1 and after 24 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 24 minus FPG at baseline). A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. Per protocol, the ertugliflozin arms were combined for this analysis.
Time frame: Baseline and Week 24
Change From Baseline in Hemoglobin A1C at Week 54
Hemoglobin A1C is a measure of the percentage of glycated HbA1C in the blood. Participant whole blood samples were collected at baseline and Week 54 to determine the A1C change from baseline (i.e., A1C at Week 54 minus A1C at baseline). A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. Per protocol, the ertugliflozin arms were combined for this analysis.
Time frame: Baseline and Week 54
Change From Baseline in FPG at Week 54
Blood glucose is measured on a fasting basis. FPG is expressed as mg/dL. Blood was drawn at predose on Day 1 and after 54 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 54 minus FPG at baseline). A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. Per protocol, the ertugliflozin arms were combined for this analysis.
Time frame: Baseline and Week 54
| Milestone | 5 mg Ertugliflozin | 5 mg/5 mg Ertugliflozin | 5 mg/15 mg Ertugliflozin | Placebo |
|---|---|---|---|---|
| Started | 63 | 22 | 26 | 55 |
| Re-randomized | 0 | 22 | 26 | 0 |
| Completed | 61 | 22 | 23 | 53 |
| Not completed | 2 | 0 | 3 | 2 |
| Withdrew: Physician decision | 0 | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 2 | 0 | 1 | 1 |
Hemoglobin A1C is a measure of the percentage of glycated HbA1C in the blood. Participant whole blood samples were collected at baseline and Week 24 to determine the A1C change from baseline (i.e., % A1C at Week 24 minus % A1C at baseline). A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. The Bayesian mean change from baseline for each combined ertugliflozin and placebo are reported. Per protocol, the ertugliflozin arms are combined for this analysis.
| A1C Percentage | Combined Ertugliflozin | Placebo |
|---|---|---|
| Change From Baseline in Hemoglobin A1C (HbA1C) at Week 24 (Combined Ertugliflozin Versus Placebo) | -0.55 (-0.82 to -0.28) | 0.12 (-0.23 to 0.47) |
An adverse event -- Select --is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. Per protocol, the ertugliflozin arms are combined for this analysis.
| Participants | Combined Ertugliflozin | Placebo |
|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) Up to Week 24 | 59 | 33 |
An adverse event is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. Per protocol, the ertugliflozin arms are combined for this analysis.
| Participants | Combined Ertugliflozin | Placebo |
|---|---|---|
| Number of Participants Who Experienced an AE Up to Week 54 | 71 | 42 |
An adverse event is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. Per protocol, the ertugliflozin arms are combined for this analysis.
| Participants | Combined Ertugliflozin | Placebo |
|---|---|---|
| Number of Participants Who Discontinued Study Treatment Due to an AE Up to Week 24 | 0 | 0 |
An adverse event is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. Per protocol, the ertugliflozin arms are combined for this analysis.
| Participants | Combined Ertugliflozin | Placebo |
|---|---|---|
| Number of Participants Who Discontinued Study Treatment Due to an AE Up to Week 54 | 0 | 1 |
Hemoglobin A1C is a measure of the percentage of glycated HbA1C in the blood. Participant whole blood samples were collected at baseline and Week 24 to determine the A1C change from baseline (i.e., % A1C at Week 24 minus % A1C at baseline). A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.
| A1C Percentage | Dose-Optimized Ertugliflozin | Placebo |
|---|---|---|
| Change From Baseline in Hemoglobin A1C at Week 24 (Dose-optimized Ertugliflozin Versus Placebo) | -0.42 (-0.76 to -0.08) | 0.25 (-0.22 to 0.72) |
Hemoglobin A1C is a measure of the percentage of glycated HbA1C in the blood. Participant whole blood samples were collected at baseline and Week 24 to determine the A1C change from baseline (i.e., % A1C at Week 24 minus % A1C at baseline). A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.
| A1C Percentage | 5 mg Ertuglifozin | Placebo |
|---|---|---|
| Change From Baseline in Hemoglobin A1C at Week 24 (5 mg Ertugliflozin Versus Placebo) | -0.54 (-0.86 to -0.22) | 0.32 (-0.11 to 0.76) |
Blood glucose is measured on a fasting basis. FPG is expressed as mg/dL. Blood was drawn at predose on Day 1 and after 24 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 24 minus FPG at baseline). A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. Per protocol, the ertugliflozin arms were combined for this analysis.
| mg/dL | Combined Ertugliflozin | Placebo |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 | -20.8 (-30.8 to -10.8) | 8.2 (-5.4 to 21.7) |
Hemoglobin A1C is a measure of the percentage of glycated HbA1C in the blood. Participant whole blood samples were collected at baseline and Week 54 to determine the A1C change from baseline (i.e., A1C at Week 54 minus A1C at baseline). A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. Per protocol, the ertugliflozin arms were combined for this analysis.
| AIC Percentage | Combined Ertugliflozin | Placebo |
|---|---|---|
| Change From Baseline in Hemoglobin A1C at Week 54 | -0.22 (-0.59 to 0.16) | 0.81 (0.24 to 1.38) |
Blood glucose is measured on a fasting basis. FPG is expressed as mg/dL. Blood was drawn at predose on Day 1 and after 54 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 54 minus FPG at baseline). A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. Per protocol, the ertugliflozin arms were combined for this analysis.
| mg/dL | Combined Ertugliflozin | Placebo |
|---|---|---|
| Change From Baseline in FPG at Week 54 | -12.1 (-23.7 to -0.5) | 21.0 (3.6 to 38.4) |
Collected over Up to 56 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 5 mg Ertugliflozin: Week 1-54 | 0/63 (0%) | 2/63 (3.2%) | 29/63 (46%) |
| 5 mg/5 mg Ertugliflozin: Week 1-54 | 0/22 (0%) | 1/22 (4.5%) | 11/22 (50%) |
| 5 mg/15 mg Ertugliflozin: Week 1-12 (Ertu 5 mg) | 0/26 (0%) | 0/26 (0%) | 8/26 (30.8%) |
| 5 mg/15 mg Ertugliflozin: Week 12-54 (Ertu 15 mg) | 0/26 (0%) | 1/26 (3.8%) | 14/26 (53.8%) |
| Placebo: Week 1-54 | 0/55 (0%) | 0/55 (0%) | 31/55 (56.4%) |
| Event | 5 mg Ertugliflozin: Week 1-54 | 5 mg/5 mg Ertugliflozin: Week 1-54 | 5 mg/15 mg Ertugliflozin: Week 1-12 (Ertu 5 mg) | 5 mg/15 mg Ertugliflozin: Week 12-54 (Ertu 15 mg) | Placebo: Week 1-54 |
|---|---|---|---|---|---|
| COVID-19 pneumoniaInfections and infestations | 0/63 | 1/22 | 0/26 | 0/26 | 0/55 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/63 | 0/22 | 0/26 | 1/26 | 0/55 |
| Post procedural infectionInfections and infestations | 1/63 | 0/22 | 0/26 | 0/26 | 0/55 |
| Foot fractureInjury, poisoning and procedural complications | 1/63 | 0/22 | 0/26 | 0/26 | 0/55 |
| Tibia fractureInjury, poisoning and procedural complications | 1/63 | 0/22 | 0/26 | 0/26 | 0/55 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/63 | 0/22 | 0/26 | 0/26 | 0/55 |
| Event | 5 mg Ertugliflozin: Week 1-54 | 5 mg/5 mg Ertugliflozin: Week 1-54 | 5 mg/15 mg Ertugliflozin: Week 1-12 (Ertu 5 mg) | 5 mg/15 mg Ertugliflozin: Week 12-54 (Ertu 15 mg) | Placebo: Week 1-54 |
|---|---|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 7/63 | 2/22 | 3/26 | 5/26 | 7/55 |
| NauseaGastrointestinal disorders | 2/63 | 3/22 | 2/26 | 4/26 | 4/55 |
| VomitingGastrointestinal disorders | 1/63 | 2/22 | 2/26 | 4/26 | 3/55 |
| Upper respiratory tract infectionInfections and infestations | 9/63 | 1/22 | 1/26 | 1/26 | 6/55 |
| HeadacheNervous system disorders | 5/63 | 1/22 | 1/26 | 3/26 | 3/55 |
| Abdominal painGastrointestinal disorders | 1/63 | 2/22 | 1/26 | 2/26 | 3/55 |
| DiarrhoeaGastrointestinal disorders | 0/63 | 2/22 | 0/26 | 1/26 | 4/55 |
| GastroenteritisInfections and infestations | 3/63 | 0/22 | 0/26 | 1/26 | 5/55 |
| PharyngitisInfections and infestations | 1/63 | 2/22 | 0/26 | 0/26 | 1/55 |
| COVID-19Infections and infestations | 5/63 | 1/22 | 0/26 | 2/26 | 4/55 |
| Age, Continuous(years) | 5 mg Ertugliflozin | 5 mg/5 mg Ertugliflozin | 5 mg/15 mg Ertugliflozin | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 14.4 ± 2.0 | 14.6 ± 2.0 | 15.6 ± 1.8 | 15.1 ± 1.7 | 14.8 ± 1.9 |
| Age, Customized(Participants) | 5 mg Ertugliflozin | 5 mg/5 mg Ertugliflozin | 5 mg/15 mg Ertugliflozin | Placebo | Total |
|---|---|---|---|---|---|
| In utero | 0 | 0 | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 | 0 | 0 |
| Children (2-11 years) | 6 | 2 | 0 | 1 | 9 |
| Adolescents (12-17 years) | 56 | 20 | 24 | 52 | 152 |
| Adults (18-64 years) | 1 | 0 | 2 | 2 | 5 |
| From 65-84 years | 0 | 0 | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | 5 mg Ertugliflozin | 5 mg/5 mg Ertugliflozin | 5 mg/15 mg Ertugliflozin | Placebo | Total |
|---|---|---|---|---|---|
| Female | 38 | 10 | 20 | 30 | 98 |
| Male | 25 | 12 | 6 | 25 | 68 |
| Ethnicity (NIH/OMB)(Participants) | 5 mg Ertugliflozin | 5 mg/5 mg Ertugliflozin | 5 mg/15 mg Ertugliflozin | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 33 | 8 | 9 | 22 | 72 |
| Not Hispanic or Latino | 30 | 13 | 17 | 33 | 93 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | 5 mg Ertugliflozin | 5 mg/5 mg Ertugliflozin | 5 mg/15 mg Ertugliflozin | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 6 | 3 | 5 | 5 | 19 |
| Asian | 7 | 5 | 3 | 10 | 25 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 4 | 1 | 5 |
| White | 43 | 12 | 13 | 31 | 99 |
| More than one race | 7 | 2 | 1 | 8 | 18 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Baseline A1C(A1C Percentage) | 5 mg Ertugliflozin | 5 mg/5 mg Ertugliflozin | 5 mg/15 mg Ertugliflozin | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 7.6 ± 1.0 | 8.5 ± 1.1 | 8.8 ± 0.9 | 8.0 ± 1.0 | 8.0 ± 1.1 |
| Insulin Use at Screening(Participants) | 5 mg Ertugliflozin | 5 mg/5 mg Ertugliflozin | 5 mg/15 mg Ertugliflozin | Placebo | Total |
|---|---|---|---|---|---|
| Yes | 18 | 14 | 17 | 24 | 73 |
| No | 45 | 8 | 9 | 31 | 93 |
| Age at Screening(Years) | 5 mg Ertugliflozin | 5 mg/5 mg Ertugliflozin | 5 mg/15 mg Ertugliflozin | Placebo | Total |
|---|---|---|---|---|---|
| 10 to 14 years of age | 27 | 11 | 8 | 23 | 69 |
| 15 to 17 years of age | 36 | 11 | 18 | 32 | 97 |
Showing the first 100 of 104 sites across 22 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Oct 2019 to primary completion in Apr 2025, 66 months.
Results were first posted in Oct 2025, 6 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 66 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ertugliflozin